Загрузка...
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents
BACKGROUND: Traditional phase I trials are designed to be conservative. Many times a traditional phase I trial design stops at a dose level below the maximal tolerated dose (MTD), thus potentially treating patients at a suboptimal level in all subsequent trials. This has been confirmed by our recent...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3744092/ https://ncbi.nlm.nih.gov/pubmed/23529697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1740774513480961 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|